U.S. FDA panel backs Celltrion copycat drug of Roche blood cancer drug

An advisory panel to the U.S. Food and Drug Administration on Wednesday voted unanimously in favor of Celltrion Pharm Inc's copycat drug of Roche Holding AG's blood cancer drug Rituxan.